Results 221 to 230 of about 7,288,800 (308)

Loss of protein C vs protein S results in discrepant thrombotic phenotypes. [PDF]

Blood Adv
Ku CJ, Yu X, Zhao QY, Grzegorski SJ, Daniel JG, Ferguson AC, Shavit JA.   +6 more
europepmc   +1 more source

Next‐generation proteomics improves lung cancer risk prediction

Molecular Oncology, EarlyView.
This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj, Clara Frick, Ben Schöttker, Bernd Holleczek, Hermann Brenner   +4 more
wiley   +1 more source

Comprehensive literature review of protein C concentrate use in patients with severe congenital protein C deficiency. [PDF]

Res Pract Thromb Haemost
Siffel C, Wadhwa A, Tongbram V, Ogongo MK, Sliwka H, Gazda HT, Turecek PL.   +6 more
europepmc   +1 more source

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

Unraveling the Molecular Pathogenesis of Protein C Deficiency-Associated VTE: Insights from Protein C Mutations C238G and R189W in Thai Patients. [PDF]

Thromb Haemost
Tanratana P, Seanoon K, Payongsri P, Kadegasem P, Chuansumrit A, Sirachainan N.   +5 more
europepmc   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

Thrombomodulin is a stronger indicator of combined oral contraceptives-induced activated protein C pathway resistance in the thrombin generation test than activated protein C. [PDF]

Front Cardiovasc Med
Ninivaggi M, Sokolova L, Donkervoort D, de Laat B, de Laat-Kremers R.   +4 more
europepmc   +1 more source

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

Molecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller, Susanne Ebner, Carmen Haselrieder, Julia K. Günther, Astrid Drasche, Sophie Strich, Chiara Volani, Andrea Medici, Aleksandar Nikolajevic, Alex Deltedesco, Johannes E. Sigmund, Michael J. Blumer, Martin Hermann, Johanna Vanacker, Gerald Brandacher, Eduard Stefan, Omar Torres‐Quesada, Jakob Troppmair   +17 more
wiley   +1 more source

Cryo-EM structure of coagulation factor Va bound to activated protein C.

Blood
Mohammed BM, Basore K, Di Cera E.
europepmc   +1 more source

Autoantibodies against endothelial protein C receptor and integrin αvβ6 predict the development of ulcerative colitis. [PDF]

J Gastroenterol
Sawahashi M, Kakuta Y, Naito T, Okazaki S, Ohneda K, Orui M, Obara T, Ogishima S, Kumada K, Kudo H, Nagami F, Hozawa A, Iwaki H, Nagai H, Shimoyama Y, Moroi R, Shiga H, Kinouchi Y, Shirai T, Fujii H, Masamune A.   +20 more
europepmc   +1 more source